Voxelotor treatment of a patient with sickle cell disease and very severe anemia.
作者信息
Shet Arun S, Mendelsohn Laurel, Harper Julia, Ostrowski David, Henry Eric R, Gwaabe Eveline, Nichols Jim, Alayash Abdu I, Eaton William A, Thein Swee Lay
机构信息
Sickle Cell Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland.
Laboratory of Chemical Physics, NIDDK National Institutes of Health, Bethesda, Maryland.
出版信息
Am J Hematol. 2019 Apr;94(4):E88-E90. doi: 10.1002/ajh.25389. Epub 2019 Jan 8.
Abstract
摘要
相似文献
1
Voxelotor treatment of a patient with sickle cell disease and very severe anemia.
Am J Hematol. 2019 Apr;94(4):E88-E90. doi: 10.1002/ajh.25389. Epub 2019 Jan 8.
2
Voxelotor use in adults with sickle cell disease in a real-world setting.
Am J Hematol. 2022 Mar 1;97(3):E125-E128. doi: 10.1002/ajh.26453. Epub 2022 Jan 10.
3
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease.
N Engl J Med. 2019 Aug 8;381(6):509-519. doi: 10.1056/NEJMoa1903212. Epub 2019 Jun 14.
4
Systematic Review of Voxelotor: A First-in-Class Sickle Hemoglobin Polymerization Inhibitor for Management of Sickle Cell Disease.
Pharmacotherapy. 2020 Jun;40(6):525-534. doi: 10.1002/phar.2405. Epub 2020 May 19.
5
Voxelotor (GBT440) produces interference in measurements of hemoglobin S.
Clin Chim Acta. 2018 Jul;482:57-59. doi: 10.1016/j.cca.2018.03.032. Epub 2018 Mar 27.
6
Voxelotor: A Novel Treatment for Sickle Cell Disease.
Ann Pharmacother. 2021 Feb;55(2):240-245. doi: 10.1177/1060028020943059. Epub 2020 Jul 16.
7
Two New Drugs for Sickle Cell Disease.
Am J Nurs. 2020 Mar;120(3):24. doi: 10.1097/01.NAJ.0000656312.23070.38.
8
Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease.
Br J Clin Pharmacol. 2019 Jun;85(6):1290-1302. doi: 10.1111/bcp.13896. Epub 2019 Mar 31.
9
Fetal Hemoglobin Decrease During Voxelotor Treatment.
Eur J Haematol. 2025 Feb;114(2):264-266. doi: 10.1111/ejh.14332. Epub 2024 Oct 21.
10
Voxelotor for the Treatment of Sickle Cell Disease.
Nurs Womens Health. 2020 Jun;24(3):233-237. doi: 10.1016/j.nwh.2020.03.003. Epub 2020 May 6.
引用本文的文献
1
Comparing the Safety and Efficacy of L-Glutamine, Voxelotor, and Crizanlizumab for Reducing the Frequency of Vaso-Occlusive Crisis in Sickle Cell Disease: A Systematic Review.
Cureus. 2022 May 11;14(5):e24920. doi: 10.7759/cureus.24920. eCollection 2022 May.
2
Treatment of sickle cell disease by increasing oxygen affinity of hemoglobin.
Blood. 2021 Sep 30;138(13):1172-1181. doi: 10.1182/blood.2021012070.
3
MWC allosteric model explains unusual hemoglobin-oxygen binding curves from sickle cell drug binding.
Biophys J. 2021 Jun 15;120(12):2543-2551. doi: 10.1016/j.bpj.2021.04.024. Epub 2021 Apr 29.
本文引用的文献
1
Case series of patients with severe sickle cell disease treated with voxelotor (GBT440) by compassionate access.
Am J Hematol. 2018 May 12. doi: 10.1002/ajh.25139.
2
Voxelotor (GBT440) produces interference in measurements of hemoglobin S.
Clin Chim Acta. 2018 Jul;482:57-59. doi: 10.1016/j.cca.2018.03.032. Epub 2018 Mar 27.
3
Treating sickle cell disease by targeting HbS polymerization.
Blood. 2017 May 18;129(20):2719-2726. doi: 10.1182/blood-2017-02-765891. Epub 2017 Apr 6.
4
Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin.
ACS Med Chem Lett. 2017 Jan 23;8(3):321-326. doi: 10.1021/acsmedchemlett.6b00491. eCollection 2017 Mar 9.
5
Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review.
Haematologica. 2006 Aug;91(8):1076-83.
Zotero 插件